Companies › Werewolf Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| WTX-330 Bispecific antibody engaging immune effector cells | – | Phase 1 | Advanced or Metastatic Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06939283 | WTX-330 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Apr 2026 |
Cash of $22m on 2026-06-30; operating cash outflow about $8m a year; runway about 33 months at that burn, to Mar 2029
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.